Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Public ClinicalTrials.gov record NCT07080242. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Study identification
- NCT ID
- NCT07080242
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- SystImmune Inc.
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
- Locally Advanced or Metastatic Large Cell Neuroendocrine Carcinoma of the Lung
- Metastatic or Locally Advanced Extrapulmonary Neuroendocrine Carcinoma
- Metastatic or Locally Advanced Merkel Cell Carcinoma
- Metastatic or Locally Advanced Neuroendocrine Prostate Cancer
- Metastatic or Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Neuroendocrine Cancer
- Poorly Differentiated and/or High Grade Neuroendocrine Neoplasms With Evidence of DLL3 Expression
- Small Cell Lung Cancer Metastatic or Locally Advanced
Interventions
- BL-M14D1 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 27, 2025
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Feb 8, 2026
2025 – 2027
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | Recruiting |
| UCLA | Los Angeles | California | 90095 | Not yet recruiting |
| UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center) | San Francisco | California | 94158 | Not yet recruiting |
| University of Colorado - Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | Not yet recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06520-8028 | Not yet recruiting |
| Emory Winship | Atlanta | Georgia | 30322 | Recruiting |
| University of Kentucky - Markey Cancer Center | Lexington | Kentucky | 40536 | Not yet recruiting |
| John Theurer Cancer Center-Hackensack | Hackensack | New Jersey | 07601 | Recruiting |
| Rutgers Cancer Institute | New Brunswick | New Jersey | 08901 | Not yet recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Not yet recruiting |
| Ohio State University | Columbus | Ohio | 43201 | Not yet recruiting |
| Providence Cancer Institute | Portland | Oregon | 97213 | Not yet recruiting |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29605 | Not yet recruiting |
| NEXT Dallas | Dallas | Texas | 75039 | Not yet recruiting |
| START Dallas- Fort Worth | Dallas | Texas | 76104 | Not yet recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| NEXT Houston | Houston | Texas | 77054 | Not yet recruiting |
| START- San Antonio | San Antonio | Texas | 78229 | Not yet recruiting |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
| University of Washington/Fred Hutchinson Cancer Center | Seattle | Washington | 98195 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07080242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07080242 live on ClinicalTrials.gov.